Chisthi MM. Current research status and future directions of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(3): 99068 [DOI: 10.4251/wjgo.v17.i3.99068]
Corresponding Author of This Article
Meer M Chisthi, MBBS, MS, Professor, Surgeon, Department of General Surgery, Government Medical College Pathanamthitta, Aanakuthi, Konni 689691, Kerala, India. meerchisthi@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Mar 15, 2025; 17(3): 99068 Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.99068
Current research status and future directions of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
Meer M Chisthi
Meer M Chisthi, Department of General Surgery, Government Medical College Pathanamthitta, Konni 689691, Kerala, India
Author contributions: Chisthi MM is responsible for all work on the manuscript.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Meer M Chisthi, MBBS, MS, Professor, Surgeon, Department of General Surgery, Government Medical College Pathanamthitta, Aanakuthi, Konni 689691, Kerala, India. meerchisthi@gmail.com
Received: July 12, 2024 Revised: October 24, 2024 Accepted: December 10, 2024 Published online: March 15, 2025 Processing time: 216 Days and 23.7 Hours
Core Tip
Core Tip: Hepatic arterial infusion chemotherapy (HAIC) has been shown to offer significantly superior efficacy and safety compared to traditional treatments such as Sorafenib and transarterial chemoembolization for patients suffering from advanced hepatocellular carcinoma. By directly delivering high concentrations of chemotherapeutic agents to the liver tumor through the hepatic artery, HAIC maximizes tumoricidal effects while minimizing systemic side effects. This article underscores the promising clinical outcomes associated with HAIC. Through continued investigation and validation, HAIC has the potential to become a cornerstone in the treatment paradigm for advanced hepatocellular carcinoma, providing patients with a more effective and safer therapeutic option.
